Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Fudan University
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Kaposiform Hemangioendotheliomas with or without Kasabach-Merritt Phenomenon.

• 0 - 12 years of age at the time of study entry.

• Male or female.

• Consent of parents (or the person having parental authority in families): Signed and dated written informed consent.

Exclusion Criteria:

• with hematological diseases.

• with other solid tumors.

• with hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency.

• with tuberculosis,cytomegalovirus and Epstein-Barr virus infection before the treatment.